Top Markets
#1 Islamic Coin Islamic Coin +152.27%
#2 Bitway Bitway +54.83%
#3 Starpower Starpower +43.85%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +28.42%
#5 aelf aelf +25.73%
#6 SkyAI SkyAI +16.02%
#7 Pons Pons +15.58%
#8 Ribbita by Virtuals Ribbita by Virtuals +15.40%
#9 DAPPOS DAPPOS +14.14%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.08%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Evaxion Biotech A/S Evaxion Biotech A/S

Evaxion Biotech A/S

EVAX
Rank in Stocks #29741
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Share Price
$3.14
Last synced: 2026-08-18
Market Cap
$19.83M
Change (1 day)
0.32%
Change (1 year)
3.29%
Country
DK
Trade Evaxion Biotech A/S (EVAX)

Category

Healthcare
Revenue for Evaxion Biotech A/S (EVAX)
Revenue in Aug 2026 TTM: 0
According to Evaxion Biotech A/S latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Evaxion Biotech A/S from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR